Holen Sie sich die Stockscreener-App
3.00
3.85%
-0.12
Handel nachbörslich:
3.06
0.06
+2.00%
Macrogenics Inc Aktie (MGNX) Neueste Nachrichten
MacroGenics at Barclays Conference: Strategic Therapeutic Focus By Investing.com - Investing.com Canada
MGNX: Multiple clinical milestones and strategic updates expected in 2026, backed by strong partnerships - TradingView
MacroGenics (NASDAQ:MGNX) Price Target Raised to $4.00 at Barclays - Defense World
MacroGenics (MGNX) Loss Of US$74.6 Million Tests Bullish Loss‑Narrowing Narrative - Sahm
MacroGenics at Leerink Global Healthcare Conference: Strategic Pipeline Focus By Investing.com - Investing.com Canada
Stifel reiterates MacroGenics stock rating with $4 price target - Investing.com
MacroGenics Inc earnings missed by $0.03, revenue topped estimates - Investing.com Nigeria
Barclays Forecasts Strong Price Appreciation for MacroGenics (NASDAQ:MGNX) Stock - MarketBeat
MacroGenics (NASDAQ:MGNX) Announces Quarterly Earnings Results, Beats Estimates By $0.20 EPS - MarketBeat
Barclays Raises Price Target for Macrogenics (MGNX) to $4.00, Maintains 'Overweight' Rating | MGNX Stock News - GuruFocus
MacroGenics, Inc. 2025 Annual Report: Innovative Antibody-Based Cancer Therapeutics, Pipeline, and Risk Factors Overview - Minichart
MGNX Closes Up 45% On Wall Street Optimism For Experimental Cancer Therapies - Stocktwits
MacroGenics (MGNX) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
MacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data Disclosures - Bitget
MacroGenics: Fourth Quarter Earnings Overview - Bitget
MacroGenics Q4 2025 Earnings: Loss Below Estimates, Revenue Beats ForecastNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
MacroGenics: Q4 Earnings Snapshot - marketscreener.com
Cancer biotech MacroGenics lines up 2026 trial data, funds into 2027 - Stock Titan
Chipmakers Recap: Can MacroGenics Inc expand its profit margins2026 Macro Moves & Low Risk Growth Stock Ideas - baoquankhu1.vn
Aug Breakouts: Can MacroGenics Inc disrupt its industryPortfolio Value Report & Long-Term Safe Investment Ideas - baoquankhu1.vn
Risk Off: Will MacroGenics Inc. stock deliver consistent dividends2025 Growth vs Value & Detailed Earnings Play Strategies - Naître et grandir
Aug Retail: Will MacroGenics Inc outperform the market in YEARJuly 2025 Macro Moves & Long-Term Growth Plans - baoquankhu1.vn
Trade Recap: Can MacroGenics Inc expand its profit marginsWeekly Volume Report & Long-Term Growth Stock Strategies - baoquankhu1.vn
MacroGenics, Inc. (NASDAQ:MGNX) Given Average Rating of "Hold" by Analysts - MarketBeat
MGNX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
MacroGenics (MGNX) director Jay Siegel to step down after 2026 meeting - Stock Titan
Whats the profit margin of MacroGenics IncEarnings Risk Report & Real-Time Volume Trigger Notifications - baoquankhu1.vn
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates C - GuruFocus
MacroGenics to Participate in Upcoming Investor Conferences - The Manila Times
Cancer drug developer MacroGenics lines up March investor talks - Stock Titan
FDA Partially Pauses Cancer Drug Trial After Patient Death - National Today
Why is MacroGenics stock sinking Tuesday? - MSN
MacroGenics (MGNX) Reports Q1 Loss, Lags Revenue Estimates - MSN
MacroGenics stock falls after FDA places partial clinical hold - Investing.com South Africa
MacroGenics stock falls after FDA places partial clinical hold By Investing.com - Investing.com Australia
MacroGenics (MGNX) Faces FDA Setback with Partial Hold on Lorige - GuruFocus
MacroGenics stock drops after FDA partial hold (MGNX:NASDAQ) - Seeking Alpha
FDA Places Partial Clinical Hold on MacroGenics Trial - TipRanks
FDA Imposes Partial Clinical Hold on MacroGenics' (MGNX) Study - GuruFocus
MacroGenics Pauses Cancer Drug Trial After Safety Issues - National Today
MacroGenics Pauses Enrollment Of Participants In LINNET Trial On FDA's Partial Clinical Hold - RTTNews
MacroGenics says FDA places partial clinical hold on Phase 2 LINNET study - TipRanks
Why Is MacroGenics Stock Sinking Tuesday? - Bitget
FDA halts new enrollment in MacroGenics (NASDAQ: MGNX) LINNET study - Stock Titan
Macrogenics announces pausing of enrollment of new study participants in Linnet trial - marketscreener.com
MacroGenics Faces Partial Clinical Hold from FDA on LINNET Study of Lorigerlimab in Gynecologic Cancers - Quiver Quantitative
FDA halts new enrollment in cancer trial after severe side effects - Stock Titan
Panic Selling: Will MacroGenics Inc outperform the market in YEAR2025 Performance Recap & Weekly Setup with High ROI Potential - baoquankhu1.vn
Armistice Capital (MGNX) discloses 6.32M shares, 9.99% stake via Master Fund - Stock Titan
MacroGenics (NASDAQ: MGNX) SVP awarded RSUs, options and exercises units - Stock Titan
MacroGenics (MGNX) VP Beth Ann Smith reports RSU vesting and new option grants - Stock Titan
Why MacroGenics Inc. stock is favored by pension fundsEarnings Beat & Accurate Entry/Exit Alerts - mfd.ru
Income Plays: Will MacroGenics Inc outperform the market in YEARPortfolio Return Report & Capital Protection Trade Alerts - baoquankhu1.vn
MGNX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Why MacroGenics Inc. stock remains a top recommendationJuly 2025 Opening Moves & Free Daily Entry Point Trade Alerts - mfd.ru
Scott Koenig increases MacroGenics (MGNX) stake via 15,831 RSU conversion - Stock Titan
MacroGenics, Inc. (NASDAQ:MGNX) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Big Picture: Is Badger Meter Inc stock suitable for long term investing2025 Bull vs Bear & Weekly Market Pulse Alerts - baoquankhu1.vn
Incyte wins EU backing for MacroGenics-partnered cancer drug in GIT indication - Seeking Alpha
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):